LENZ Therapeutics operates as an organization engaged in the late-stage clinical development of pharmaceuticals for the eyes.
LENZ Therapeutics has raised $30.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in July 2024.
LENZ Therapeutics's investors include RA Capital Management, Samsara BioCapital, Alpha Wave Global, Point72, RTW Investments.
LENZ Therapeutics is headquartered in Del Mar, United States.
LENZ Therapeutics operates as an organization engaged in the late-stage clinical development of pharmaceuticals for the eyes.
LENZ Therapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"LENZ Therapeutics — Funding & Investors." VCBacked, July 15, 2024, https://www.vcbacked.co/company/lenz-therapeutics. Accessed November 11, 2026.
VCBacked. (2024). LENZ Therapeutics — Funding & Investors. Retrieved November 11, 2026, from https://www.vcbacked.co/company/lenz-therapeutics
{{cite web |title=LENZ Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/lenz-therapeutics |website=VCBacked |access-date=November 11, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at LENZ Therapeutics? Request a listing update